Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma

Objective: The aim of this study was to evaluate and validate the proposed 8th edition American Joint Committee on Cancer (AJCC) system for T and N staging of pancreatic adenocarcinoma. Summary of Background Data: Investigators have questioned the clinical relevance and reproducibility of previous AJCC staging for pancreatic adenocarcinoma. Methods: Prospective databases at Memorial Sloan Kettering (MSK), Massachusetts General Hospital (MGH), and Johns Hopkins Hospital (JHH) were queried for patients who had undergone resection for pancreatic adenocarcinoma. Patients who underwent a margin-negative (R0) resection, and who had previously undergone pathologic review, were included. Patients were staged according to 7th edition AJCC criteria, as well as the proposed 8th edition system that includes different definitions of tumor size (T) and nodal status (N). The dataset was randomly split into training and test sets. Results: Two thousand three hundred eighteen patients were identified who met inclusion criteria. Recursive partitioning on the training set (n = 1551) identified statistically appropriate cutoffs for tumor size (<2.2 cm, ≥4.8 cm,) and nodal status (no positive nodes, 1 to 3 positive nodes, ≥4 positive nodes) that supported the proposed 8th edition changes. Median survival in patients staged as T3, N0 by the 7th edition definitions was different between institutions (median Center 1, 24 mo; Center 2, 37 mo; Center 3, 29 mo; P = 0.054). This difference was not observed when patients were staged as T3, N0 by 8th edition criteria. Stage, and stage-specific outcome (7th edition), on the test set revealed a predominance of patients (68%) within the IIB subgroup, and a concordance probability estimate (CPE) of 0.57 for stage-specific survival. When assessed with 8th edition criteria, no stage subgroup had a majority of patients, and the CPE was 0.58. Conclusions: The proposed 8th edition changes for T and N classification were statistically valid and may allow a more reproducible system of T staging. This system also stratifies patients more evenly across stages without sacrificing prognostic accuracy.

[1]  D. Gouma,et al.  Question Sets and Answers , 2014, Surgery.

[2]  Sudeshna,et al.  Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System (pT1: , 2022 .

[3]  G. Wilding,et al.  Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. , 2012, Journal of gastrointestinal oncology.

[4]  T. Keck,et al.  The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer , 2009, Journal of Gastrointestinal Surgery.

[5]  H. Ohge,et al.  Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. , 2010, Journal of the American College of Surgeons.

[6]  F. Harrell,et al.  Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.

[7]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[8]  T. Therneau,et al.  Number of Lymph Nodes Evaluated: Prognostic Value in Pancreatic Adenocarcinoma , 2012, Journal of Gastrointestinal Surgery.

[9]  Olca Basturk,et al.  Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. , 2012, Seminars in diagnostic pathology.

[10]  R. Abrams,et al.  Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. , 2012, International journal of radiation oncology, biology, physics.

[11]  M. Gönen,et al.  Prognostic Significance of Pathologic Nodal Status in Patients with Resected Pancreatic Cancer , 2007, Journal of Gastrointestinal Surgery.

[12]  Laura H. Tang,et al.  Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades , 2011, Annals of Surgical Oncology.

[13]  A. Krasinskas,et al.  Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging , 2015, Annals of Surgical Oncology.

[14]  K. Lillemoe,et al.  Recurrence and Survival After Resection of Small Intraductal Papillary Mucinous Neoplasm-associated Carcinomas (⩽20-mm Invasive Component): A Multi-institutional Analysis , 2016, Annals of surgery.

[15]  T. Meyer,et al.  Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  M. Büchler,et al.  Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories. , 2015, Annals of surgery.